Clinical trials: Advanced Solid Tumors Patients
Advanced Solid Tumors
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
This is open-label, multicenter, Phase Ib study is designed to evaluate the Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in participants with advanced solid tumors.
- Trial name
- NCT05172856
- Testing
- IBI321
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cancer
A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.
- Trial name
- NCT00869895
- Testing
- E7050
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
Advanced Solid Tumors
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
This is a multi- center, open-label, dose finding, Phase Ib study to be conducted in two stages: a dose escalation part to determine the maximum tolerated dose (MTD) safety and tolerability of concurrent administration of MEK162…
- Trial name
- NCT01352273
- Testing
- MEK162 + RAF265
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 69 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Advanced or Metastatic Solid Tumors
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors.
- Trial name
- NCT05785754
- Testing
- DCSZ11, Pembrolizumab, Doxorubicin
- Where
- 35 sites in United States, Australia and 2 more
- Volunteers
- 320 people
- Sponsor
- DynamiCure Biotechnology
Carcinoma, Renal Cell, Glioblastoma
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment while the majority of patients will eventually…
- Conditions
- Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular
- Trial name
- NCT01441388
- Testing
- Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib
- Sponsor
- Pfizer
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Solid Tumor, Lymphoma
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.
- Trial name
- NCT05357651
- Testing
- LB1410
- Where
- China
- Volunteers
- 100 people
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China
Advanced Solid Tumors
A Study of AK146D1 for Injection in Advanced Solid Tumors
This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.
- Trial name
- NCT07067567
- Testing
- AK146D1 for injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Akeso
Advanced Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
This Phase Ib/II study is an openlabel, multicenter study for patients with solid tumors and breast cancer amenable to anthracyclin therapy.
- Trial name
- NCT01131364
- Testing
- F16IL2 in combination with doxorubicin
- Where
- 5 sites in Italy
- Volunteers
- 29 people
- Sponsor
- Philogen S.p.A.
Advanced Solid Tumors
A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
A phase Ⅰ clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of GEN-725 tablets in patients with advanced solid tumors.
- Trial name
- NCT07229898
- Testing
- GEN-725 tablets
- Where
- 4 sites in China
- Volunteers
- 48 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Solid Tumor, Adult
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and…
- Trial name
- NCT04130516
- Testing
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Linnaeus Therapeutics, Inc.
Neoplasm Malignant
A Study of PSB205 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, Phase 1, ascending dose escalation study of PSB205 in subjects with advanced solid tumors. The study will be conducted in 2 parts.
- Trial name
- NCT03986606
- Testing
- PSB205
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Neoplasms
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
This study will investigate the drug-drug interactions (DDIs) between rucaparib and oral rosuvastatin (Arm A), and between rucaparib and oral ethinylestradiol and levonorgestrel (Arm B), with rucaparib as a perpetrator.
- Trial name
- NCT03954366
- Testing
- Rucaparib, Rosuvastatin, Oral Contraceptives
- Where
- 7 sites in Hungary, Poland and 1 more
- Volunteers
- 36 people
- Sponsor
- pharmaand GmbH
Solid Tumors, Chronic Lymphocytic Leukemia
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
This is a four-part dose-escalation and confirmation study in participants with advanced solid tumors. Part A is for dose escalation and determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of…
- Conditions
- Solid Tumors, Chronic Lymphocytic Leukemia, T-cell-prolymphocytic Leukemia
- Trial name
- NCT00749502
- Testing
- MK-4827
- Volunteers
- 113 people
- Sponsor
- Tesaro, Inc.
Advanced Malignant Solid Tumors
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab…
- Trial name
- NCT05949775
- Testing
- Neoantigen mRNA Personalised Cancer vaccine
- Volunteers
- 20 people
- Sponsor
- Stemirna Therapeutics
Renal Cancer, Tumors
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sorafenib will be determined. In part 2, with the MTD as a starting point, a group of patients will be accrued with the goal of…
- Trial name
- NCT00398814
- Testing
- Perifosine, Sorafenib
- Volunteers
- 30 people
- Sponsor
- AEterna Zentaris
Unspecified Adult Solid Tumor, Protocol Specific
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00004216
- Testing
- salmonella VNP20009, cefixime, ceftriaxone sodium
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
- Trial name
- NCT03875313
- Testing
- CB-839, Talazoparib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Calithera Biosciences, Inc
Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1.
- Trial name
- NCT03733990
- Testing
- FP-1305 (bexmarilimab)
- Where
- 11 sites in United States, Finland and 4 more
- Volunteers
- 216 people
- Sponsor
- Faron Pharmaceuticals Ltd
Advanced Solid Tumor, Breast Cancer
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.
- Conditions
- Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Ovary Cancer
- Trial name
- NCT05465590
- Testing
- MB1707
- Sponsor
- Mainline Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.